Multiple myeloma, immunotherapy and minimal residual disease
نویسندگان
چکیده
منابع مشابه
Minimal residual disease in multiple myeloma.
Multiple myeloma (MM) is a B-cell malignancy in which abnormal, clonal plasma cells proliferate and accumulate in the bone marrow. These abnormal cells, referred to as myeloma cells, disrupt normal bone marrow function and invade bone. Myeloma cells produce and secrete significant quantities of monoclonal protein (M-protein) into the blood and/or urine.1 The clinical features of MM include hype...
متن کاملNovel Immunotherapy to Eliminate Minimal Residual Disease in AML Patients
Even with the most sophisticated chemotherapy regimens, the majority of patients with acute myeloid leukemia will eventually experience a relapse and die from their disease. New treatments are needed to prevent relapse of disease in these patients. Immunotherapy using the host immune system to combat leukemia represents an exciting and potentially efficacious addition to standard chemotherapy f...
متن کاملImmunotherapy for Multiple Myeloma
1Clinic for Stem Cell Transplantation, Center of Oncology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany 2 Service d’Hématologie Clinique, Hôpital Hôtel-Dieu, CHU de Nantes, Place Alexis Ricordeau, 44093 Nantes Cedex, France 3Hematology and Bone Marrow Transplantation, Internal Medicine, Chaim Sheba Medical Center, 52621 Tel-Hashomer, Israel 4Department o...
متن کاملImmunotherapy in Multiple Myeloma
The treatment of multiple myeloma has evolved significantly over the past decades, spanning from alkylator-based therapy to the more recent novel therapies that include proteasome inhibition and immunomodulatory agents. The introduction of immunotherapy to the treatment landscape of multiple myeloma has led to the development of new strategies and therapies that engage the immune system to enha...
متن کاملMinimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
With contemporary therapeutic strategies in multiple myeloma, heretofore unseen depth and rate of responses are being achieved. These strategies have paralleled improvements in outcome of multiple myeloma patients. The integration of the next generation of proteasome inhibitors and antibody therapeutics promise continued improvements in therapy with the expectation of consistent depth of respon...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neoplasma
سال: 2016
ISSN: 1338-4317
DOI: 10.4149/neo_2016_501